Apriem Advisors Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Apriem Advisors trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 14,494 shares of the biopharmaceutical company’s stock after selling 1,033 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 1.2% of Apriem Advisors’ investment portfolio, making the stock its 25th biggest position. Apriem Advisors’ holdings in Regeneron Pharmaceuticals were worth $10,325,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $37,000. Private Wealth Management Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 39 shares during the period. Finally, Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.3 %

NASDAQ:REGN opened at $706.94 on Thursday. The stock has a fifty day simple moving average of $698.68 and a 200-day simple moving average of $874.30. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $77.29 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $11.86 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on REGN shares. TD Cowen dropped their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Barclays dropped their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.